Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aldeyra Therapeu (NQ: ALDX )

13.37 USD +1.18 (+9.68%)
Streaming Delayed Price Updated: 4:07 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,107,639
Open 12.35
Bid (Size) 13.01 (2)
Ask (Size) 13.51 (3)
Prev. Close 12.19
Today's Range 12.31 - 13.60
52wk Range 1.480 - 12.75
Shares Outstanding 20,109,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with... 
From Business Wire News Releases
Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with... 
From Business Wire News Releases

Performance

YTD
+104.75%
+104.75%
1 Month
+94.05%
+94.05%
3 Month
+94.90%
+94.90%
6 Month
+108.26%
+108.26%
1 Year
+113.92%
+113.92%

More News

Read More
Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect 2021 Virtual Conference
From Business Wire News Releases
Aldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease
From Business Wire News Releases
Aldeyra Therapeutics to Host Conference Call and Webcast to Discuss Top-Line Symptom, Redness, and Schirmer’s Test Results from Run-in Cohort of Phase 3 TRANQUILITY Trial
From Business Wire News Releases
Aldeyra Therapeutics Announces Confirmation of Antiviral Activity of ADX-1612
From Business Wire News Releases
Aldeyra Therapeutics Announces Initiation of Phase 2 Clinical Trials of ADX-629, a First-in-Class Orally Administered RASP Inhibitor, for the Treatment of COVID-19, Atopic Asthma, and Psoriasis
From Business Wire News Releases
Why Aldeyra Therapeutics Stock Is Jumping Today
Tags ALDX Market News
From Motley Fool
Aldeyra Announces First Patient Enrolled in the Phase 3 TRANQUILITY Trial of Reproxalap for the Treatment of Dry Eye Disease
From Business Wire News Releases
Thinking about buying stock in T2 Biosystems, Zomedica, Aldeyra Therapeutics, La Jolla Pharmaceutical, or US Well Services?
From PR Newswire
Analysts Forecast 15% Gains Ahead For The Holdings of PTH
Tags ETFs
From ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.